Compare BFC & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFC | TSHA |
|---|---|---|
| Founded | 1894 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2018 | 2020 |
| Metric | BFC | TSHA |
|---|---|---|
| Price | $145.57 | $6.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $157.00 | $11.63 |
| AVG Volume (30 Days) | 73.7K | ★ 2.6M |
| Earning Date | 04-16-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ 11.23 | 5.56 |
| EPS | ★ 7.23 | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | $58.67 | N/A |
| Revenue Next Year | $2.01 | $1,152.42 |
| P/E Ratio | $19.88 | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $109.11 | $1.85 |
| 52 Week High | $153.00 | $6.76 |
| Indicator | BFC | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 59.68 | 70.56 |
| Support Level | $118.88 | $4.39 |
| Resistance Level | $150.50 | N/A |
| Average True Range (ATR) | 4.97 | 0.40 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 74.95 | 89.58 |
Bank First Corp is a United States-based company engaged in providing financial services, a full range of consumer and commercial financial institution services to individuals and businesses, including retail and commercial banking in Wisconsin. These services include credit cards; secured and unsecured consumer, commercial, and real estate loans; demand, time, and savings deposits; and ATM processing. The Corporation also offers a full line of insurance services and checking accounts, savings accounts, money market accounts, cash management accounts, certificates of deposit, commercial and industrial loans, commercial real estate loans, construction and development loans, residential mortgages, consumer loans, credit cards, online banking, telephone banking, and mobile banking.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.